<!DOCTYPE html>
<html lang="en">
	<head>
		<meta charset="UTF-8">
		<title>Xiidra_First_and_Only_728x90</title>
		<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
        <meta name="ad.size" content="width=728,height=90">
        <link href="https://fonts.googleapis.com/css?family=Montserrat:300,600,700" rel="stylesheet">
    <style>
        * { margin:0;padding:0;box-sizing:border-box;}
        div {position:absolute;background-repeat:no-repeat !important;}
        #loader{width:728px;height:90px;}
    </style>
    <script type="text/javascript">
        var clickTag = "https://www.xiidra-ecp.com",
            clickTag1 = "http://www.shirecontent.com/PI/PDFS/XIIDRA_USA_ENG.pdf";
    </script>
	</head>
    <body>
    <div id="loader"></div>
    <div class="banner" style="display: none">
        <div id="bg" class="bg"></div>
    	<div id="i0_1" class="i0"></div>
    	<div id="i0_2" class="i0"></div>

    	<div id="copy_f1_01" class="copy_f1_01">
                <div id="i1" class="i1">
                    <svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 25 13" style="enable-background:new 0 0 25 13;" xml:space="preserve">
                        <style type="text/css">
                            .sti1_1{fill:#FFFFFF;}
                            .sti1_2{fill:#63B1E5;}
                        </style>
                        <path class="sti1_1"  id="i1a" d="M17.1.7.1,1.8.2,5.3l16.9-.8a16.681,16.681,0,0,0,0-3.8Z"/>
                        <circle class="sti1_2" cx="22.4" cy="2.9" r="2.5"/>
                        <path class="sti1_1"  id="i1b" d="M.5,8.1,17.4,7a18.1,18.1,0,0,1,.1,1.917,18.1,18.1,0,0,1-.1,1.883L.6,11.6Z"/>
                        <circle class="sti1_2" cx="22.2" cy="9.1" r="2.5"/>
                    </svg>
                </div>
                <div id="i1" class="i1"></div>
        </div>
        <div id="copy_f4_01" class="copy_f4_01"></div>
        <div id="copy_f4_02" class="copy_f4_02 retina"></div>
    	<div id="i3_1" class="i3"></div>
    	<div id="i3_2" class="i3"></div>
        <div id="logoXiidra"></div>
        <div id="FPILink"><p><span id="link">Full Prescribing Information</<span></p></div>
        <div id="cta" class="cta">
            <div id="ctaArrw"></div>
        </div>
    	<div id="btnExit"></div>
        <div id="isi" class="ISIanim">
            <div id="FPILink"><p><span id="link">Full Prescribing Information</<span></p></div>
            <div id="isi-text" class="content">
                <h3 >Important Safety Information</h3>

               <!-- ident from here -->
                   <p class="p">Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.</p>

                    <p class="p margin-large">In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.</p>

                    <p><span id="scrollForMore">Scroll for more Important Safety Information</span></p>

                    <p class="p margin-large">To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.</p>

                    <p class="p margin-large">Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.</p>

                    <p class="p margin-large">Safety and efficacy in pediatric patients below the age of 17 years have not been established.</p>

                 <h3 class="h-short-space-paragraph">Indication</h3>
                <p class="p margin-short">Xiidra<sup>&#x00ae;</sup> (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).</p>

                <p class="p margin-large">
                    Please <span class="p-link-bold">click here for Full Prescribing Information</span>.
                </p>

                <p class="p margin-large">
                    <span id="logoShire"></span>
                    &copy; 2018 Shire US Inc. All Rights Reserved. S38405 04/18
                </p>
            </div>
            <div id="isi-controls"></div>
        </div>
	</div>
    <script src="ScrollToPlugin.js"></script>
    <script src="MorphSVGPlugin.min.js"></script>
	<script src="TweenMax.min.js"></script>
	<script type="text/javascript" src="main.js"></script>
    <script type="text/javascript">

    elem("#btnExit").addEventListener('click', clickTagHandler);
    elem(".p-link-bold").addEventListener('click', clickTagHandler1);
    elem("#FPILink").addEventListener('click', clickTagHandler1);

    function clickTagHandler(){ window.open(window.clickTag);}
    function clickTagHandler1(){ window.open(window.clickTag1);}

    function elem(id){return document.querySelector(id)};

    </script>
	</body>
</html>
